Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb
- PMID: 16488698
- DOI: 10.1016/j.athoracsur.2005.09.022
Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb
Abstract
Background: Nitric oxide released by pulmonary vascular endothelium is a potent vasodilator related to increased cyclic guanosine monophosphate (cGMP) content. Hydrolysis of cGMP is achieved predominately by cGMP-specific phosphodiesterases. Sildenafil is a selective phosphodiesterase-5 (PDE5) inhibitor. The purpose of the study is to assess the effects of sildenafil on pulmonary vascular circulation during the perinatal period.
Methods: Thirty-two pregnant ewes were operated on at the end of gestation, and fetal lambs were prepared with catheters placed into the aorta, vena cava, pulmonary artery, and left atrium. An ultrasonic flow transducer and an inflatable vascular occluder were placed respectively around the left pulmonary artery and the ductus arteriosus. Fetal lambs were randomly divided into two groups: (1) sildenafil group, infused continuously with sildenafil for 24 hours at a rate of 1 mg/h; or (2) control group, infused with saline for 24 hours. After 24 hours of infusion, we compared basal pulmonary vascular resistance and the pulmonary vascular responses to increase in fetal PaO2 and to acute ductus arteriosus compression causing "shear stress."
Results: Sildenafil infusion did not change mean aortic and pulmonary artery pressures, increased mean left pulmonary blood flow by 160%, and decreased pulmonary vascular resistance by 60% (p < 0.05). However, both mean flow (Q) and pulmonary vascular resistance returned to baseline values after 2 hours of sildenafil infusion. Despite similar baseline values, pulmonary vascular resistance during maternal O2 inhalation was lower in the sildenafil group than in the control group (0.21 +/- 0.03 versus 0.33 +/- 0.03 mm Hg.mL(-1).min(-1), respectively; p < 0.01). Furthermore, drop in pulmonary vascular resistance during acute ductus arteriosus compression was greater in the sildenafil group (from 0.56 +/- 0.06 to 0.26 +/- 0.04 mm Hg.mL(-1).min(-1)) than in the control group (from 0.55 +/- 0.05 to 0.39 +/- 0.03 mm Hg.mL(-1).min(-1); p < 0.01).
Conclusions: Although sildenafil induces a transient pulmonary vasodilation, it mediates a sustained change in vascular reactivity, especially to birth-related stimuli in the ovine fetal lung. These data suggest that PDE5 is involved in the regulation of pulmonary vascular reactivity during the perinatal period and may potentiate birth-related pulmonary vasodilator stimuli.
Similar articles
-
Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.Circulation. 2003 Sep 9;108 Suppl 1:II167-73. doi: 10.1161/01.cir.0000087384.76615.60. Circulation. 2003. PMID: 12970227 Clinical Trial.
-
Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.Anesthesiology. 2000 Jun;92(6):1702-12. doi: 10.1097/00000542-200006000-00030. Anesthesiology. 2000. PMID: 10839922
-
Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L727-33. doi: 10.1152/ajplung.00409.2004. Epub 2004 Dec 17. Am J Physiol Lung Cell Mol Physiol. 2005. PMID: 15608146
-
Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.Curr Opin Pharmacol. 2005 Jun;5(3):245-50. doi: 10.1016/j.coph.2004.12.008. Curr Opin Pharmacol. 2005. PMID: 15907910 Review.
-
Sildenafil: emerging cardiovascular indications.Ann Thorac Surg. 2004 Oct;78(4):1496-506. doi: 10.1016/j.athoracsur.2004.02.125. Ann Thorac Surg. 2004. PMID: 15464535 Review.
Cited by
-
Maternal sildenafil impairs the cardiovascular adaptations to chronic hypoxaemia in fetal sheep.J Physiol. 2020 Oct;598(19):4405-4419. doi: 10.1113/JP279248. Epub 2020 Aug 11. J Physiol. 2020. PMID: 32754905 Free PMC article.
-
Molecular physiopathogenetic mechanisms and development of new potential therapeutic strategies in persistent pulmonary hypertension of the newborn.Ital J Pediatr. 2015 Feb 8;41:6. doi: 10.1186/s13052-015-0111-0. Ital J Pediatr. 2015. PMID: 25887340 Free PMC article. Review.
-
Decreased Cyclic Guanosine Monophosphate-Protein Kinase G Signaling Impairs Angiogenesis in a Lamb Model of Persistent Pulmonary Hypertension of the Newborn.Am J Respir Cell Mol Biol. 2021 Nov;65(5):555-567. doi: 10.1165/rcmb.2020-0434OC. Am J Respir Cell Mol Biol. 2021. PMID: 34185619 Free PMC article.
-
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.Glob Cardiol Sci Pract. 2014 Oct 16;2014(3):257-90. doi: 10.5339/gcsp.2014.42. eCollection 2014. Glob Cardiol Sci Pract. 2014. PMID: 25780785 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous